Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
30 hedge funds and large institutions have $394M invested in Sinovac Biotech, Ltd in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
2,000% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 1
864% more capital invested
Capital invested by funds: $40.8M → $394M (+$353M)
200% more funds holding
Funds holding: 10 → 30 (+20)
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$349M |
| 2 |
Renaissance Technologies
New York
|
+$1.54M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.04M |
| 4 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
+$259K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$179K |
Top Sellers
SVA Hedge Fund Activity: Q2 2022 in Review
30 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q2 2022, worth a combined $394M — up 864% from $40.8M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new SVA positions and 1 closed out — a net gain of 20 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $349M.
- 30 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q2 2022, up from 10 in Q1 2022.
- Funds reported $394M of Sinovac Biotech, Ltd stock for Q2 2022, up 864% quarter-over-quarter.
- 21 funds opened new Sinovac Biotech, Ltd positions in Q2 2022 and 1 closed out, a net change of +20 holders.
- The largest Sinovac Biotech, Ltd buyer in Q2 2022 was OrbiMed, an estimated $349M added.
Based on aggregated 13F filings for Q2 2022.